Axsome Therapeutics Net Worth
Axsome Therapeutics Net Worth Breakdown | AXSM |
Axsome Therapeutics Net Worth Analysis
Axsome Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Axsome Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Axsome Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Axsome Therapeutics' net worth analysis. One common approach is to calculate Axsome Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Axsome Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Axsome Therapeutics' net worth. This approach calculates the present value of Axsome Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Axsome Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Axsome Therapeutics' net worth. This involves comparing Axsome Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Axsome Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Axsome Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Axsome Therapeutics' net worth research are outlined below:
| Axsome Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 270.6 M. Net Loss for the year was (239.24 M) with profit before overhead, payroll, taxes, and interest of 308.29 M. | |
| Axsome Therapeutics currently holds about 73.39 M in cash with (145.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Axsome Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Axsome Moves 11.5 percent Higher Will This Strength Last |
Axsome Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Axsome Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Axsome Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Axsome Therapeutics Target Price Consensus
Axsome target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Axsome Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 17 | Strong Buy |
Most Axsome analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Axsome stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Axsome Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAxsome Therapeutics Target Price Projection
Axsome Therapeutics' current and average target prices are 91.94 and 131.18, respectively. The current price of Axsome Therapeutics is the price at which Axsome Therapeutics is currently trading. On the other hand, Axsome Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Axsome Therapeutics Market Quote on 19th of January 2025
Target Price
Analyst Consensus On Axsome Therapeutics Target Price
Know Axsome Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Axsome Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Axsome Therapeutics backward and forwards among themselves. Axsome Therapeutics' institutional investor refers to the entity that pools money to purchase Axsome Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Eventide Asset Management, Llc | 2024-09-30 | 827.9 K | Perceptive Advisors Llc | 2024-09-30 | 782.8 K | Wellington Management Company Llp | 2024-09-30 | 742.7 K | Alethea Capital Management, Llc | 2024-09-30 | 738.5 K | Bank Of America Corp | 2024-09-30 | 727.5 K | Amvescap Plc. | 2024-09-30 | 625.2 K | Hood River Capital Management Llc | 2024-09-30 | 625.1 K | Point72 Asset Management, L.p. | 2024-09-30 | 542.6 K | Adage Capital Partners Gp Llc | 2024-09-30 | 525 K | Rtw Investments, Llc | 2024-09-30 | 4.2 M | Vanguard Group Inc | 2024-09-30 | 4 M |
Follow Axsome Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.54 B.Market Cap |
|
Project Axsome Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.46) | (0.49) | |
| Return On Assets | (0.37) | (0.38) | |
| Return On Equity | (1.44) | (1.37) |
When accessing Axsome Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Axsome Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Axsome Therapeutics' profitability and make more informed investment decisions.
Evaluate Axsome Therapeutics' management efficiency
Axsome Therapeutics has return on total asset (ROA) of (0.2644) % which means that it has lost $0.2644 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7161) %, meaning that it created substantial loss on money invested by shareholders. Axsome Therapeutics' management efficiency ratios could be used to measure how well Axsome Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of January 2025, Return On Tangible Assets is likely to drop to -0.43. In addition to that, Return On Capital Employed is likely to drop to -0.49. At this time, Axsome Therapeutics' Other Assets are very stable compared to the past year. As of the 19th of January 2025, Intangibles To Total Assets is likely to grow to 0.18, while Return On Tangible Assets are likely to drop (0.43).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.83 | 5.08 | |
| Tangible Book Value Per Share | 3.18 | 3.34 | |
| Enterprise Value Over EBITDA | (17.46) | (18.33) | |
| Price Book Value Ratio | 17.04 | 17.89 | |
| Enterprise Value Multiple | (17.46) | (18.33) | |
| Price Fair Value | 17.04 | 17.89 | |
| Enterprise Value | 3.1 B | 3.2 B |
Leadership at Axsome Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 13.0161 | Revenue | Quarterly Revenue Growth 0.813 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Axsome Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Axsome Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Axsome Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Axsome Therapeutics Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 24th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Axsome Therapeutics Earnings Estimation Breakdown
The calculation of Axsome Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Axsome Therapeutics is estimated to be -1.317325 with the future projection ranging from a low of -1.4825 to a high of -0.915. Please be aware that this consensus of annual earnings estimates for Axsome Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.48 Lowest | Expected EPS | -0.92 Highest |
Axsome Therapeutics Earnings Projection Consensus
Suppose the current estimates of Axsome Therapeutics' value are higher than the current market price of the Axsome Therapeutics stock. In this case, investors may conclude that Axsome Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Axsome Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 17 | 76.89% | -1.3419 | -1.317325 | -6.45 |
Axsome Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Axsome Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Axsome Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Axsome Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Axsome Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Axsome Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Axsome Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Axsome Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Axsome Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -1.41 | -1.3419 | 0.0681 | 4 | ||
2024-08-05 | 2024-06-30 | -1.33 | -1.67 | -0.34 | 25 | ||
2024-05-06 | 2024-03-31 | -1.2 | -1.44 | -0.24 | 20 | ||
2024-02-20 | 2023-12-31 | -1.17 | -2.08 | -0.91 | 77 | ||
2023-11-06 | 2023-09-30 | -1.2 | -1.32 | -0.12 | 10 | ||
2023-08-07 | 2023-06-30 | -1.22 | -1.54 | -0.32 | 26 | ||
2023-05-08 | 2023-03-31 | -1.04 | -0.26 | 0.78 | 75 | ||
2023-02-27 | 2022-12-31 | -1.14 | -1.41 | -0.27 | 23 | ||
2022-11-07 | 2022-09-30 | -1.08 | -1.07 | 0.01 | 0 | ||
2022-08-09 | 2022-06-30 | -1.21 | -1.06 | 0.15 | 12 | ||
2022-05-02 | 2022-03-31 | -1 | -1.03 | -0.03 | 3 | ||
2022-03-01 | 2021-12-31 | -1.02 | -0.9 | 0.12 | 11 | ||
2021-11-08 | 2021-09-30 | -0.95 | -0.93 | 0.02 | 2 | ||
2021-08-09 | 2021-06-30 | -0.96 | -0.86 | 0.1 | 10 | ||
2021-05-10 | 2021-03-31 | -0.87 | -0.78 | 0.09 | 10 | ||
2021-03-01 | 2020-12-31 | -0.76 | -0.78 | -0.02 | 2 | ||
2020-11-05 | 2020-09-30 | -0.57 | -0.58 | -0.01 | 1 | ||
2020-08-10 | 2020-06-30 | -0.62 | -0.49 | 0.13 | 20 | ||
2020-05-08 | 2020-03-31 | -0.62 | -0.88 | -0.26 | 41 | ||
2020-03-12 | 2019-12-31 | -0.48 | -0.71 | -0.23 | 47 | ||
2019-11-07 | 2019-09-30 | -0.4 | -0.56 | -0.16 | 40 | ||
2019-08-08 | 2019-06-30 | -0.33 | -0.41 | -0.08 | 24 | ||
2019-05-09 | 2019-03-31 | -0.3 | -0.32 | -0.02 | 6 | ||
2019-03-14 | 2018-12-31 | -0.3 | -0.32 | -0.02 | 6 | ||
2018-11-09 | 2018-09-30 | -0.29 | -0.31 | -0.02 | 6 | ||
2018-08-08 | 2018-06-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2018-05-08 | 2018-03-31 | -0.28 | -0.19 | 0.09 | 32 | ||
2018-03-07 | 2017-12-31 | -0.31 | -0.31 | 0.0 | 0 | ||
2017-11-08 | 2017-09-30 | -0.34 | -0.27 | 0.07 | 20 | ||
2017-08-09 | 2017-06-30 | -0.34 | -0.3 | 0.04 | 11 | ||
2017-05-09 | 2017-03-31 | -0.39 | -0.41 | -0.02 | 5 | ||
2017-03-07 | 2016-12-31 | -0.42 | -0.4 | 0.02 | 4 | ||
2016-11-14 | 2016-09-30 | -0.39 | -0.38 | 0.01 | 2 | ||
2016-08-09 | 2016-06-30 | -0.39 | -0.36 | 0.03 | 7 | ||
2016-05-11 | 2016-03-31 | -0.28 | -0.31 | -0.03 | 10 | ||
2016-03-24 | 2015-12-31 | -0.22 | -0.12 | 0.1 | 45 |
Axsome Therapeutics Corporate Management
| Hunter Esq | General Secretary | Profile | |
| Amanda PharmD | Senior Development | Profile | |
| Lori MBA | Executive Development | Profile | |
| Kevin PharmD | Ex Strategy | Profile | |
| Mark MA | Chief Officer | Profile |
Already Invested in Axsome Therapeutics?
The danger of trading Axsome Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Axsome Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Axsome Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Axsome Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.45) | Revenue Per Share | Quarterly Revenue Growth 0.813 | Return On Assets | Return On Equity |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.